For example, ASO-mediated correction restores CD22 exon 2 inclusion to overcome resistance to inotuzumab ozogamicin, induces ΔEx3 PD-1 to reinvigorate exhausted T cells [96,157], and shifts splicing toward the sVEGFR2 isoform to inhibit tumor angiogenesis [171]. The gene discussed is PDCD1; the disease is neoplasm.